Category: Prohost Letters
Improving on immunotherapy and preventing one of its serious side effects
The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. Removal of glutamine leads to a substantial reduction in cell growth or induces cell death in certain types of cancer cells , indicating that...
Read More
November 13, 2018
0
The ASCO 2019 Special Edition
Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed victim of the instigated and irrelevant fear against investing in the stock market is the market itself. Indeed, baseless fear campaigns frighten positive investors...
Read More
June 11, 2019
0
The Week in Review #10
The Week in Review #10 NO CONSPIRACY THEORIES - But this is what’s happening - In the past issue of The Week in Review, we wrote about the irrational pattern of selling the biotech stocks during the announcement of the...
Read More
November 6, 2017
0
Prohost Letter #414
Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s updates and comments...
Read More
October 25, 2017
0
When common sense fails to explain market performance
Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual for the stock market to be in a selloff mood for a few days . However, in the last couple of months, the market...
Read More
December 3, 2018
0
Treating Hemoglobinopathies
Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell disease ( SCD ) and beta-thalassemia. Millions of people around the world are affected by these two conditions in which genetic defects impact the...
Read More
June 21, 2019
0
The Week in Review #11
The Week in Review #11 A New Era - Faster than the speed of light, the management of diseases is shifting from fast improvement to a total gigantic unprecedented change. Some of the conquering approaches towards providing long-lasting cures look as...
Read More
November 20, 2017
0
Politics and the Market
The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, the Prime Minister of England, delayed the Brexit vote! The question becomes, what will be put forth next as a legitimate reason for bringing...
Read More
December 11, 2018
0
Answering Your Questions
The Week in Review #12 Answering You - Many questions still need answers in the biotech’s fast moving universe and we are doing our best to answer them. We found out that we should start answering questions even though we...
Read More
December 1, 2017
0
Last Week's Promising News
The Week in Review #13 From the Prohost Portfo lio - 1. Betting on the technology - HALOZYME - As expected, the pulse of fat agreements with HALO is accelerating... ...
Read More
December 11, 2017
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)